Logo for Atomo Diagnostics Limited

Atomo Diagnostics Investor Relations Material

Latest events

Logo for Atomo Diagnostics Limited

Q3 2024

Atomo Diagnostics
Logo for Atomo Diagnostics

Q3 2024

30 Apr, 2024
Logo for Atomo Diagnostics

H1 2024

26 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Atomo Diagnostics Limited

Access all reports
Atomo Diagnostics Limited provides products in the areas of cancer, infectious diseases, and cardiovascular ailments. Its tests include Visca for diagnosing liver cancer and liver fibrosis/cirrhosis; MammaScreen for early breast cancer detection through measurements of plasma proteins (by testing blood); Chlamydia Screen for the screening or confirmation of Chlamydia trachomatis infections; HIV-1Virology Test System for the qualitative detection of antibodies to human immunodeficiency virus type 1 (HIV-1); and AtomoRapid Malaria Test that detects malaria infection in whole blood samples. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.